SAB Biotherapeutics (NASDAQ:SABS) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of SAB Biotherapeutics (NASDAQ:SABS) from a hold rating to a strong sell rating in a research note issued to investors on Thursday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday. UBS Group initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 price objective on the stock. Guggenheim initiated coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Chardan Capital increased their target price on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Stock Performance

SABS opened at $4.15 on Thursday. The business’s 50 day moving average is $4.02 and its 200-day moving average is $3.36. The stock has a market cap of $211.44 million, a PE ratio of -1.79 and a beta of 0.59. The company has a current ratio of 9.46, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). On average, analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the 4th quarter valued at $34,000. ADAR1 Capital Management LLC lifted its holdings in shares of SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares during the period. State Street Corp bought a new position in SAB Biotherapeutics during the fourth quarter valued at about $49,000. Fifth Lane Capital LP bought a new position in SAB Biotherapeutics during the fourth quarter valued at about $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter worth about $32,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.